Maternal and Postnatal Outcomes Study (MOS): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

计划入组 10 人 · 首次发布于 2025 年 4 月 23 日

A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

计划入组 100 人 · 首次发布于 2024 年 10 月 29 日

Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion

计划入组 23 人 · 首次发布于 2022 年 1 月 11 日

Pegunigalsidase alfa(Elfabrio)

bifikafusp alfa + onfekafusp alfa

Apadamtase alfa /Cinaxadamtase alfa

Alfa Wassermann SpA

Italy

Hospital General Puyo

Ecuador

Protalix Biotherapeutics

Israel

Chiesi's ELFABRIO Shows Promise in Phase 3 Trial for Fabry Disease with Twice-Dose Regimen

Elfabrio Shows Promise in Phase 3 BRIGHT Study for Fabry Disease

Sangamo Therapeutics' Fabry Disease Candidate ST-920 Gains Accelerated Approval Pathway